Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NKTR logo NKTR
Upturn stock ratingUpturn stock rating
NKTR logo

Nektar Therapeutics (NKTR)

Upturn stock ratingUpturn stock rating
$48.68
Last Close (24-hour delay)
Profit since last BUY64.02%
upturn advisory
Strong Buy
BUY since 55 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/12/2025: NKTR (3-star) is a STRONG-BUY. BUY since 55 days. Simulated Profits (64.02%). Updated daily EoD!

Upturn Star Rating

rating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $96.17

1 Year Target Price $96.17

Analysts Price Target For last 52 week
$96.17 Target price
52w Low $6.48
Current$48.68
52w High $50.53

Analysis of Past Performance

Type Stock
Historic Profit 82.94%
Avg. Invested days 34
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 4.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/12/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 925.83M USD
Price to earnings Ratio -
1Y Target Price 96.17
Price to earnings Ratio -
1Y Target Price 96.17
Volume (30-day avg) 8
Beta 1.07
52 Weeks Range 6.48 - 50.53
Updated Date 09/14/2025
52 Weeks Range 6.48 - 50.53
Updated Date 09/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -8.64

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -163.17%
Operating Margin (TTM) -320.21%

Management Effectiveness

Return on Assets (TTM) -31.57%
Return on Equity (TTM) -440.8%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 846077133
Price to Sales(TTM) 12.36
Enterprise Value 846077133
Price to Sales(TTM) 12.36
Enterprise Value to Revenue 11.29
Enterprise Value to EBITDA -6.5
Shares Outstanding 19018600
Shares Floating 17594272
Shares Outstanding 19018600
Shares Floating 17594272
Percent Insiders 0.71
Percent Institutions 48.51

ai summary icon Upturn AI SWOT

Nektar Therapeutics

stock logo

Company Overview

overview logo History and Background

Nektar Therapeutics was founded in 1990 and is a biopharmaceutical company with a history of pioneering drug delivery technologies. Initially focused on polymer chemistry, it transitioned to developing its own pipeline of drug candidates.

business area logo Core Business Areas

  • Drug Discovery and Development: Focuses on discovering and developing novel drug candidates using its proprietary polymer conjugation technology platform. This involves research, preclinical studies, clinical trials, and regulatory submissions.
  • License and Royalties: Generates revenue through licensing its technology and drug candidates to other pharmaceutical companies, receiving royalties on sales of products developed using its technology.

leadership logo Leadership and Structure

The company is led by a CEO and a management team responsible for strategic direction and operations. The organizational structure includes departments for research, development, clinical trials, regulatory affairs, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • NKTR-255 (IL-15 Agonist): An IL-15 agonist immunotherapy being developed for cancer. Competitors include companies developing other IL-15 therapies and immunotherapies like Sanofi and Merck. Clinical trials are underway to assess its effectiveness. Market share is currently 0, pending approval and launch.
  • Onzeald (etirinotecan pegol): A topoisomerase I inhibitor approved in Europe for the treatment of adult patients with metastatic breast cancer with brain metastases. Revenue from Onzeald is very limited due to regional restriction of use. Competitors include companies with chemotherapy treatments and targeted therapies like Daiichi Sankyo.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. It is driven by innovation and the need for new and improved therapies for various diseases.

Positioning

Nektar Therapeutics is positioned as a company with expertise in polymer conjugation technology, which it uses to develop novel drug candidates. Its competitive advantage lies in its proprietary technology platform and its ability to improve the efficacy and safety of existing drugs and develop novel therapeutics.

Total Addressable Market (TAM)

The global oncology market is estimated to be in the hundreds of billions of dollars. Nektar's positioning within this TAM is dependent on the success of its pipeline products, especially NKTR-255. However, the total addressable market of Nektar is limited as they are only developing novel drug candidates in niche markets.

Upturn SWOT Analysis

Strengths

  • Proprietary polymer conjugation technology
  • Experience in drug development
  • Potential for improved drug efficacy and safety
  • Clinical pipeline

Weaknesses

  • Dependence on R&D success
  • High cash burn rate
  • Limited revenue streams
  • Regulatory hurdles

Opportunities

  • Partnerships with pharmaceutical companies
  • Expansion of pipeline into new therapeutic areas
  • Potential for breakthrough therapies
  • Advancements in polymer technology

Threats

  • Clinical trial failures
  • Competition from other biopharmaceutical companies
  • Regulatory setbacks
  • Patent expirations

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • MRK
  • BMY
  • AZN

Competitive Landscape

Nektar faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Its advantages lie in its innovative technology and targeted approach to drug development. Its current reliance on pipeline success is a competitive disadvantage.

Growth Trajectory and Initiatives

Historical Growth: Nektar's historical growth has been inconsistent, with periods of significant growth followed by setbacks due to clinical trial failures and partnership dissolutions.

Future Projections: Future growth prospects depend heavily on the success of its pipeline products, particularly NKTR-255 and other ongoing clinical programs. Analyst estimates vary widely due to the inherent uncertainty of biopharmaceutical development.

Recent Initiatives: Recent strategic initiatives include focusing on its core assets, streamlining operations, and exploring partnerships to advance its pipeline.

Summary

Nektar Therapeutics is a biopharmaceutical company with an innovative drug delivery platform but faces significant challenges. Its strengths lie in its technology, but its weaknesses include its reliance on clinical trial success and limited revenue. Success hinges on advancing its pipeline and securing strategic partnerships. Financial performance remains a key area to watch, as cash flow issues will continue to be problematic for the company.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC filings
  • Company website
  • Analyst reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The biopharmaceutical industry is inherently risky, and past performance is not indicative of future results.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Nektar Therapeutics

Exchange NASDAQ
Headquaters San Francisco, CA, United States
IPO Launch date 1994-05-03
CEO, President & Director Mr. Howard W. Robin
Sector Healthcare
Industry Biotechnology
Full time employees 61
Full time employees 61

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.